The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Ryaltris
olopatadine hydrochloride and mometasone furoate · OLOPATADINE HYDROCHLORIDE 665 ug/1; MOMETASONE FUROATE MONOHYDRATE 25 ug/1 · Spray, Metered · Nasal · Hikma Specialty Usa Inc.
NDC 59467-0700-84 · 12 CARTON in 1 BOX / 1 BOTTLE, SPRAY in 1 CARTON / 56 SPRAY, METERED in 1 BOTTLE, SPRAY · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 59467-0700-27) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$8.12per unit
middle half $7.80–$8.23 · 1,117 plans · Apr 1, 2026
Est. net of rebatesⓘ
$4.87–$6.09
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
20%of plans cover it
tier 3 · prior auth 1% · step therapy 24% · qty limit 1%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for olopatadine hydrochloride and mometasone furoate (other) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- NDA211746
- TE code
- —
- Approval date
- Jan 13, 2022
- Patents / exclusivity
- 17 patents, 1 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NPP | Jul 7, 2029 |
| patent | 12653833 | Nov 21, 2044 |
| patent | 12303635 | Apr 8, 2039 |
| patent | 11679210 | Sep 3, 2038 |
| patent | 11400101 | Sep 4, 2034 |
| patent | 12064442 | Sep 4, 2034 |
| patent | 10016443 | Sep 4, 2034 |
| patent | 10517880 | Sep 4, 2034 |
| patent | 9750754 | Sep 4, 2034 |
| patent | 10765686 | Sep 4, 2034 |
| patent | 10561672 | Sep 4, 2034 |
| patent | 9370483 | Sep 4, 2034 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · OngoingSep 24, 2024Glenmark Pharmaceuticals Inc., USA — Defective Delivery System: The dip tube is clogged causing the spray not to work.
Manufacturers of olopatadine hydrochloride and mometasone furoate (Spray, Metered)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc., USA | OLOPATADINE HYDROCHLORIDE 665 ug/1; MOMETASONE FUROATE MONOHYDRATE 25 ug/1 | Aug 26, 2026 | Sep 2, 2026 |
| Hikma Specialty Usa Inc. | OLOPATADINE HYDROCHLORIDE 665 ug/1; MOMETASONE FUROATE MONOHYDRATE 25 ug/1 | Aug 26, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | OLOPATADINE HYDROCHLORIDE 25 ug/1; MOMETASONE FUROATE MONOHYDRATE 665 ug/1 | Jul 22, 2026 | Aug 19, 2026 |
| Hikma Specialty Usa Inc. | OLOPATADINE HYDROCHLORIDE 25 ug/1; MOMETASONE FUROATE MONOHYDRATE 665 ug/1 | Jul 22, 2026 | Aug 19, 2026 |
| Glenmark Pharmaceuticals Inc., USA | MOMETASONE FUROATE MONOHYDRATE 25 ug/1; OLOPATADINE HYDROCHLORIDE 665 ug/1 | Jul 15, 2026 | Jul 15, 2026 |
| Hikma Specialty Usa Inc. | MOMETASONE FUROATE MONOHYDRATE 25 ug/1; OLOPATADINE HYDROCHLORIDE 665 ug/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Ryaltris — NDC 59467-0700-84," retrieved September 3, 2026, https://drugdashboards.com/drug/59467070084.
Free to cite with attribution — see how the data is put together.